TY - JOUR
T1 - Mobile health adherence for the detection of recurrent recent-onset atrial fibrillation
AU - van der Velden, Rachel M. J.
AU - Pluymaekers, Nikki A. H. A.
AU - Dudink, Elton A. M. P.
AU - Luermans, Justin G. L. M.
AU - Meeder, Joan G.
AU - Heesen, Wilfred F.
AU - Lenderink, Timo
AU - Widdershoven, Jos W. M. G.
AU - Bucx, Jeroen J. J.
AU - Rienstra, Michiel
AU - Kamp, Otto
AU - van Opstal, Jurren M.
AU - Kirchhof, Charles J. H. J.
AU - van Dijk, Vincent F.
AU - Swart, Henk P.
AU - Alings, Marco
AU - Van Gelder, Isabelle C.
AU - Crijns, Harry J. G. M.
AU - Linz, Dominik
N1 - © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/1
Y1 - 2023/1
N2 - OBJECTIVE: The Rate Control versus Electrical Cardioversion Trial 7-Acute Cardioversion versus Wait and See trial compared early to delayed cardioversion for patients with recent-onset symptomatic atrial fibrillation (AF). This study aims to evaluate the adherence to a 4-week mobile health (mHealth) prescription to detect AF recurrences after an emergency department visit.METHODS: After the emergency department visit, the 437 included patients, irrespective of randomisation arm (early or delayed cardioversion), were asked to record heart rate and rhythm for 1 min three times daily and in case of symptoms by an electrocardiography-based handheld device for 4 weeks (if available). Adherence was appraised as number of performed measurements per number of recordings asked from the patient and was evaluated for longitudinal adherence consistency. All patients who used the handheld device were included in this subanalysis.RESULTS: 335 patients (58% males; median age 67 (IQR 11) years) were included. The median overall adherence of all patients was 83.3% (IQR 29.9%). The median number of monitoring days was 27 out of 27 (IQR 5), whereas the median number of full monitoring days was 16 out of 27 (IQR 14). Higher age and a previous paroxysm of AF were identified as multivariable adjusted factors associated with adherence.CONCLUSIONS: In this randomised trial, a 4-week mHealth prescription to monitor for AF recurrences after an emergency department visit for recent-onset AF was feasible with 85.7% of patients consistently using the device with at least one measurement per day. Older patients were more adherent.TRIAL REGISTRATION NUMBER: NCT02248753.
AB - OBJECTIVE: The Rate Control versus Electrical Cardioversion Trial 7-Acute Cardioversion versus Wait and See trial compared early to delayed cardioversion for patients with recent-onset symptomatic atrial fibrillation (AF). This study aims to evaluate the adherence to a 4-week mobile health (mHealth) prescription to detect AF recurrences after an emergency department visit.METHODS: After the emergency department visit, the 437 included patients, irrespective of randomisation arm (early or delayed cardioversion), were asked to record heart rate and rhythm for 1 min three times daily and in case of symptoms by an electrocardiography-based handheld device for 4 weeks (if available). Adherence was appraised as number of performed measurements per number of recordings asked from the patient and was evaluated for longitudinal adherence consistency. All patients who used the handheld device were included in this subanalysis.RESULTS: 335 patients (58% males; median age 67 (IQR 11) years) were included. The median overall adherence of all patients was 83.3% (IQR 29.9%). The median number of monitoring days was 27 out of 27 (IQR 5), whereas the median number of full monitoring days was 16 out of 27 (IQR 14). Higher age and a previous paroxysm of AF were identified as multivariable adjusted factors associated with adherence.CONCLUSIONS: In this randomised trial, a 4-week mHealth prescription to monitor for AF recurrences after an emergency department visit for recent-onset AF was feasible with 85.7% of patients consistently using the device with at least one measurement per day. Older patients were more adherent.TRIAL REGISTRATION NUMBER: NCT02248753.
KW - Male
KW - Humans
KW - Aged
KW - Female
KW - Atrial Fibrillation/therapy
KW - Anti-Arrhythmia Agents/therapeutic use
KW - Heart Rate
KW - Telemedicine
KW - Electric Countershock
KW - Recurrence
U2 - 10.1136/heartjnl-2022-321346
DO - 10.1136/heartjnl-2022-321346
M3 - Article
C2 - 36322782
SN - 1355-6037
VL - 109
SP - 26
EP - 33
JO - Heart
JF - Heart
IS - 1
ER -